Physician profile
Mac Bohanan
NPI 1861017139
$1,622.17
in general payments reported to CMS, 2019-2025
24 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.80 · 2021: $309 · 2022: $359 · 2023: $417 · 2024: $133 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.08 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $505.07 | 2022-2025 | Briviact, Zilbrysq |
| Livanova USA, INC. | $172.28 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $108.32 | 2025 | Austedo Xr |
| Amgen INC. | $81.48 | 2022-2025 | Uplizna |
| Pfizer INC. | $78.62 | 2021-2025 | |
| Greenwich Biosciences, INC. | $74.39 | 2020-2021 | |
| Sk Life Science, INC. | $72.01 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $57.95 | 2022-2023 | Dysport |
| Nevro Corp. | $55.19 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $53.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $52.65 | 2023-2025 | |
| Allergan, INC. | $45.10 | 2020-2021 | |
| Genzyme Corporation | $35.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.77 | 2022 | |
| Emd Serono, INC. | $28.99 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.67 | 2025 | Symbravo |
| Hospira, INC. | $23.00 | 2023 | |
| Neurelis, INC. | $21.29 | 2025 | Valtoco |
| Kedrion Biopharma, INC. | $21.00 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Astrazeneca Pharmaceuticals Lp | $16.39 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.33 | 2021 | |
| Ns Pharma, INC. | $15.41 | 2023 | Viltepso |
| Alexion Pharmaceuticals, INC. | $14.85 | 2023 | Ultomiris |
| Novocure INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mac Bohanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.